Evidence map›Paper›PMID 36851158›Full record

ReviewVaccines2023

A Systematic Review on the Safety and Efficacy of COVID-19 Vaccines Approved in Saudi Arabia.

Thekra Ali Alhandod, Syed Imam Rabbani, Mansour Almuqbil, Sultan Alshehri, Syed Arif Hussain, Nasser Fawzan Alomar, Manzoor Ahmad Mir, Syed Mohammed Basheeruddin Asdaq

Open access · goldAbstract readReview
In one paragraph

Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Parents' views on pediatric COVID-19 vaccine in Saudi Arabia.Journal of family medicine and primary care · 2024
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Thekra Ali AlhandodDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Syed Imam RabbaniDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.ORCID 0000-0001-6344-1071
Mansour AlmuqbilDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Sultan AlshehriDepartment of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia.
Syed Arif HussainRespiratory Care Department, College of Applied Sciences, Almaarefa University, Riyadh 13713, Saudi Arabia.
Nasser Fawzan AlomarEquame Scientific and Research Center, Riyadh 13713, Saudi Arabia.
Manzoor Ahmad MirDepartment of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar 190006, India.
Syed Mohammed Basheeruddin AsdaqDepartment of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia.ORCID 0000-0003-1533-9667
Alfaisal University · SAQassim University · SAAlmaarefa UniversityKing Saud University · SAUniversity of Kashmir · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Comprehensive safety and efficacy studies of COVID-19 vaccines might reduce the apprehension of the general population about the adverse reactions and duration of protection offered by them. The study aimed to conduct a systemic review on the four COVID-19 vaccines (AstraZeneca, Pfizer, Moderna, and Janssen) approved in Saudi Arabia. The study was conducted by reviewing the published articles from electronic databases such as PubMed, Embase, Cochrane Library and Web of Science using the search terms "COVID-19", "Vaccine", "Safety", "Efficacy" and "Human trials" and as per the standard guidelines for systemic review. The review analyzed eighteen articles and the data from them were evaluated to analyze the safety and efficacy of the vaccines in different groups of population such as males, females, those above 18 years and people with co-morbidities. The common local reactions observed after vaccination were pain at the site of injection (40-70%), redness (16-30%), swelling (18-39%) and tenderness (20-40%). The systemic reactions reported were fever (40-60%), chills (12-23%), fatigue (44-65%), headache (30-42%) and muscle pain (15-40%). The efficacy was observed to be above the threshold value (60%) stipulated by the WHO. However, precautions need to be followed while vaccinating special groups of population such as those that are pregnant, lactating or experiencing severe illness. Additionally, the rare and serious adverse events reported remotely after vaccination need more studies.

Indexed as

COVID-19 vaccinesefficacysafetySaudi Arabiasystemic review

Identifiers

PMID36851158
PMCPMC9962734
OpenAlexW4318479207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.